Trade

with

Novavax Inc
(NASDAQ: NVAX)
AdChoices
5.13
+0.14
+2.81%
After Hours :
5.13
0.00
0.00%

Open

5.01

Previous Close

4.99

Volume (Avg)

5.76M (3.28M)

Day's Range

4.99-5.25

52Wk Range

2.68-6.95

Market Cap.

1.22B

Dividend Rate ( Yield )

-

Beta

1.27

Shares Outstanding

238.41M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Biotechnology
Highlights
Analyst Recommendation: Buy
    • Revenue

    • 20.92M

    • Net Income

    • -51.98M

    • Market Cap.

    • 1.22B

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -208.49

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 1.27

    • Forward P/E

    • -13.16

    • Price/Sales

    • 35.21

    • Price/Book Value

    • 4.34

    • Price/Cash flow

    • -17.15

      • EBITDA

      • -49.21M

      • Return on Capital %

      • -30.14

      • Return on Equity %

      • -34.78

      • Return on Assets %

      • -30.14

      • Book Value/Share

      • 1.18

      • Shares Outstanding

      • 238.41M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/21/2014
      Buy
        • 1 Year Price Target

        • 10.00

        • Credit Rating

        • -

        • Analysts

        • 1

        • EPS Estimate

        • -0.39

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 133.90

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • 81.43

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 55.58

            • 82.75

            • Pre-Tax Margin

            • -208.48

            • 39.38

            • Net Profit Margin

            • -208.49

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • 69.30

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -4,545.50

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • 0.00

              • 0.76

              • Current Ratio

              • 9.53

              • 2.92

              • Quick Ratio

              • 9.21

              • 2.35

              • Interest Coverage

              • -311.94

              • 38.02

              • Leverage Ratio

              • 1.11

              • 2.21

              • Book Value/Share

              • 1.18

              • 4.79

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -16.45

                • 217.39

                • P/E Ratio 5-Year High

                • -22.89

                • 634.30

                • P/E Ratio 5-Year Low

                • -3.69

                • 124.82

                • Price/Sales Ratio

                • 34.25

                • 9.52

                • Price/Book Value

                • 4.22

                • 8.61

                • Price/Cash Flow Ratio

                • -17.15

                • 50.51

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • -34.78

                    (-46.20)

                  • 37.63

                    (27.20)

                  • Return on Assets %

                    (5-Year Average)

                  • -30.14

                    (-36.70)

                  • 17.22

                    (13.81)

                  • Return on Capital %

                    (5-Year Average)

                  • -34.25

                    (-44.10)

                  • 21.78

                    (17.31)

                  • Income/Employee

                  • -

                  • 117.08k

                  • Inventory Turnover

                  • -

                  • 1.48

                  • Asset Turnover

                  • 0.14

                  • 0.55

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  -52.43M
                  Operating Margin
                  -250.70
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  -17.15
                  Ownership

                  Institutional Ownership

                  60.11%

                  Top 10 Institutions

                  36.07%

                  Mutual Fund Ownership

                  40.07%

                  Float

                  82.89%

                  5% / Insider Ownership

                  1.20%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Fidelity® Select Biotechnology Portfolio

                  •  

                    14,411,821

                  • 0.00

                  • 6.04

                  • PowerShares Dynamic Pharmaceuticals Port

                  •  

                    8,741,825

                  • 0.00

                  • 4.39

                  • T. Rowe Price Health Sciences Fund

                  •  

                    4,622,400

                  • 88.65

                  • 1.94

                  • Wells Fargo Advantage Discovery Fund

                  •  

                    4,113,967

                  • 0.48

                  • 1.73

                  • Fidelity® Advisor Small Cap Opps Fund

                  •  

                    3,775,362

                  • 26.71

                  • 1.58

                  • Vanguard Total Stock Mkt Idx

                  •  

                    3,621,534

                  • 0.00

                  • 1.52

                  • iShares Russell 2000 (AU)

                  •  

                    3,542,925

                  • -1.46

                  • 1.78

                  • SPDR® S&P Biotech ETF

                  •  

                    3,289,404

                  • -1.92

                  • 1.65

                  • iShares Nasdaq Biotechnology

                  •  

                    3,084,422

                  • -0.47

                  • 1.55

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Fidelity Management and Research Company

                  •  

                    24,914,161

                  • -10.42%

                  • 10.46

                  • T. Rowe Price Associates, Inc.

                  •  

                    10,214,700

                  • +219.83%

                  • 4.29

                  • BlackRock Fund Advisors

                  •  

                    7,089,127

                  • -8.69%

                  • 2.98

                  • Invesco PowerShares Capital Mgmt LLC

                  •  

                    7,071,863

                  • +31.35%

                  • 2.97

                  • Vanguard Group, Inc.

                  •  

                    6,831,384

                  • +14.97%

                  • 2.87

                  • RA Capital Management, LLC

                  •  

                    6,661,731

                  • -32.97%

                  • 2.80

                  • State Street Corp

                  •  

                    6,166,949

                  • -3.52%

                  • 2.59

                  • Camber Capital Management LLC

                  •  

                    4,750,000

                  • +111.11%

                  • 1.99

                  • Wells Capital Management Inc.

                  •  

                    4,701,040

                  • +47.57%

                  • 1.97

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Biotechnology

                  Type

                  Speculative Growth

                  Style

                  Small Growth

                  Novavax, Inc. was incorporated in 1987 under the laws of the State of Delaware. The Company is a clinical-stage Biopharmaceutical company focused on creating differentiated, value- upon current preventive options for a range of infec...moretious diseases. The Company manages its business as one operating segment: developing recombinant vaccines. The Company’s technology platform is based on proprietary recombinant vaccine technology that includes virus-like particles (‘VLPs’) and recombinant nanoparticle vaccines combined with a single-use bioprocessing production system. These vaccine candidates are genetically engineered three-dimensional nanostructures that incorporate immunologically important recombinant proteins. Its influenza VLPs contain three of the structural virus proteins that are important for...more fighting influenza: hemagglutinin (HA) and neuraminidase (NA), both of which stimulate the body to produce antibodies that neutralize the influenza virus and prevent its spread through the cells in the respiratory tract, and matrix 1 (M1), which stimulates cytotoxic T lymphocytes to kill cells that may already be infected. The Company’s product pipeline targets a variety of infectious diseases and its vaccine candidates are currently in or have completed clinical trials that target pandemic influenza (H5N1), seasonal influenza and respiratory syncytial virus (‘RSV’). The Company’s main competitors includes sanofi pasteur, Inc, MedImmune, LLC (a subsidiary of AstraZeneca PLC), GlaxoSmithKline plc, Novartis, Inc., and Merck & Co., Inc., Protein Sciences Corporation. The Company is subject to regulation under the Occupational Safety and Health Act, the Environmental Protection Act, the Toxic Substances Control Act, the Resource Conservation and Recovery Act and other present and potential federal, state or local regulations.lessless

                  Key People

                  Stanley C. Erck

                  CEO/Director/President

                  James F. Young

                  Chairman of the Board/Director

                  Barclay A. Phillips

                  CFO/Chief Accounting Officer/Senior VP/Treasurer

                  Mr. John A. Herrmann, III

                  General Counsel/Secretary/Vice President

                  John O. Marsh,Jr

                  Director Emeritus

                  • Novavax Inc

                  • 20 Firstfield Road

                  • Garthersburg, MD 20878

                  • USA.Map

                  • Phone: +1 240 268-2000

                  • Fax: -

                  • novavax.com

                  Incorporated

                  1987

                  Employees

                  213

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: